Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.42 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28118305 | 0.85 | GAA (0.56) | GAAKDM4EALDH1A1HPGDHTT | |
| SCHEMBL3611417 | 0.76 | TDP1 (0.54) | GAAKDM4EALDH1A1HPGDHTT | |
| SCHEMBL7623426 | 0.76 | MAOB (0.49) | GAAKDM4EALDH1A1HPGDHTT | |
| SCHEMBL28175543 | 0.73 | KMT2A (0.62) | GAAKDM4EALDH1A1HPGDHTT | |
| SCHEMBL21306242 | 0.73 | CALM1 (0.61) | GAAKDM4EALDH1A1HPGDHTT | |
| SCHEMBL594018 | 0.72 | MAPT (0.62) | GAAKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL15958609 | 0.72 | L3MBTL1 (0.58) | GAAKDM4EALDH1A1HPGDHTT | |
| SCHEMBL11166760 | 0.72 | ALDH1A1 (0.62) | GAAKDM4EALDH1A1HPGDHTT | |
| SCHEMBL3994363 | 0.72 | MEN1 (0.47) | GAAKDM4EALDH1A1HPGDHTT | |
| SCHEMBL7628856 | 0.72 | MEN1 (0.53) | GAAKDM4EALDH1A1HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10160756-B2 | Antiviral compounds and methods using same | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-12-25 | — | — | US | disclosed |
| US-20170174678-A1 | NOVEL ANTIVIRAL COMPOUNDS AND METHODS USING SAME | Rhe Trustees of The University of Pennsylvania | 2017-06-22 | — | — | US | disclosed |
| US-20170174678-A1 | NOVEL ANTIVIRAL COMPOUNDS AND METHODS USING SAME | Rhe Trustees of The University of Pennsylvania | 2017-06-22 | — | — | US | disclosed |
| US-20170174678-A1 | NOVEL ANTIVIRAL COMPOUNDS AND METHODS USING SAME | Rhe Trustees of The University of Pennsylvania | 2017-06-22 | — | — | US | disclosed |
| EP-3126005-A1 | NOVEL ANTIVIRAL COMPOUNDS AND METHODS USING SAME | The Trustees Of The University Of Pennsylvania (US) | 2017-02-08 | — | — | EP | disclosed |
| WO-2015153554-A1 | NOVEL ANTIVIRAL COMPOUNDS AND METHODS USING SAME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-10-08 | — | — | WO | disclosed |
| WO-2015153554-A1 | NOVEL ANTIVIRAL COMPOUNDS AND METHODS USING SAME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174678-A1 | NOVEL ANTIVIRAL COMPOUNDS AND METHODS USING SAME | ZC3HAV1, MAVS, ZC3HAV1L | GAA 640/4885KDM4E 2044/4885ALDH1A1 3536/4885 |
| US-10160756-B2 | Antiviral compounds and methods using same | ZC3HAV1, MAVS, ZC3HAV1L | GAA 346/4885KDM4E 1978/4885ALDH1A1 3087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.